Volrustomig Priming Regimens Exploratory Phase II Platform Study

Key Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with nodeterioration.

• Life expectancy greater than or equal to (>=) 12 weeks.

• Adequate organ and bone marrow function.

• Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.

• Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQmNSCLC in substudy 2.

• Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.

• Absence of documented tumor genomic alteration results from tests conducted as partof standard local practice in any other actionable driver oncogenes for which thereare locally approved targeted 1L therapies.

• At least one measurable lesion not previously irradiated that can be accuratelymeasured at baseline as >= 10 millimeter (mm) in the longest diameter.

Key Exclusion Criteria:

• Spinal cord compression.

• History of primary active immunodeficiency.

• Active or prior documented autoimmune or inflammatory disorders.

• Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.

• Brain metastases unless asymptomatic, stable, and not requiring steroids for atleast 14 days prior to start of study intervention. A minimum of 2 weeks must haveelapsed between the end of radiation therapy and study enrollment.

• Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participantswho have received prior platinum-containing adjuvant, neoadjuvant, or definitivechemoradiation for local disease are eligible, provided that progression hasoccurred greater (>) 12 months from end of last therapy.